XTLBIO CLOSES $31.4M VIVOQUEST ACQUISITION

XTL Biopharmaceuticals Ltd. has announced the closing of the license and asset purchase agreement signed with US company VivoQuest Inc. in August. The agreement gives XTLbio an exclusive license to VivoQuest's intellectual property and technology, including HCV compounds and VivoQuest's proprietary compound library. Industry sources say this is the first time an Israeli biotechnology company has bought a US company.

Globes

(http://www.globes.co.il/serveen/globes/DocView.asp?did=1000014615&fid=1725)